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data in oncology – the majority of appraisals did not consider utility data in line
with the NICE reference case. Even where the reference case was adhered to, often
data did not come from trials of the intervention being appraised. This will intro-
duce obvious uncertainty when evaluating the impact of the intervention on
QALYs.
PCN144
ACCESS TO CANCER INTERVENTIONS ACROSS THE UK: TO WHAT EXTENT
DOES SMC ADVICE AGREE WITH NICE’S END-OF-LIFE THERAPIES?
Hamerslag L, Brooks-Rooney C
Costello Medical Consulting Ltd., Cambridge, UK
OBJECTIVES: In January 2009, the National Institute for Health and Clinical Excel-
lence (NICE) introduced the end-of-life criteria, which give more weight to QALYs
for life-extending, end-of-life interventions. Since then, a number of therapies
have been recommended by NICE under these criteria that may not have been
approved otherwise. However, it has not been ascertained whether this increase in
access to important cancer treatments has been mirrored in Scotland. The aim of
this study was to review the advice of the Scottish Medicines Consortium (SMC) on
the end-of-life interventions approved by NICE. METHODS: All NICE single tech-
nology appraisals on cancer treatments issued between December 2008 and June
2012 were reviewed. All interventions that were approved under the end-of-life
regulations were identified, and NICE’s acceptance was compared with the advice
given by the SMC. RESULTS: In total, 9 cancer interventions were approved under
the end-of-life criteria, all of which had also been submitted for similar indications
to the SMC. Only 2 of these therapies were accepted for full use by the SMC, both
after resubmissions including patient access schemes (PAS). Of the remaining 7
interventions, 3 were not recommended by the SMC, and in 2 of these cases this
was stated to be due to a lack of sufficiently robust economic evidence. The other 4
treatments were accepted for restricted use; 2 of these after resubmissions and 1
with a PAS. CONCLUSIONS: Of the 9 cancer interventions approved by NICE under
the end-of-life criteria, 3 were not recommended by the SMC, and 4 out of the
remaining 6 were only accepted after resubmissions. The introduction of the end-
of-life criteria by NICE may therefore have contributed to differences in access to
cancer interventions within the UK, a trend potentially further exacerbated by the
introduction of the Cancer Drugs Fund in England.
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OBJECTIVES: Tobacco smoking is the leading cause of early death and morbidity in
the Western World. The causal association between smoking and a range of can-
cers, heart disease and chronic obstructive lung disease is well-established. Nu-
merous publications show that increased tobacco prices leads to lower tobacco
consumption. The aim of this study is to show the aggregated price elasticity be-
tween sale of cigarettes and price on cigarettes in Denmark from 1978 to 2010.
METHODS: Data on the price of cigarettes is from Statistics Denmark table PRIS1
(1978-2000) and PRIS6 (2000-2010). The price index of cigarettes was deflated with
the consumer price index. Data on sale of cigarettes in Denmark is from Statistics
Denmark table ALKO4. Price elasticity was estimated with OLS regression. Data
were analyzed in SAS version 9.2. RESULTS: The real price of cigarettes has de-
creased in Denmark between 1978 and 2010. The estimated crude aggregated price
elasticity for cigarettes in Denmark from 1978-2010 -0.4 (p 0.015) which is in line
with results for other countries. CONCLUSIONS: The price on cigarettes is a tool to
regulate the consumption of cigarettes. A tool that have not yet been used in
Denmark where there have been a decrease in the real price of cigarettes. Studies
have shown that especially youth and lower income groups have high price elas-
ticity on tobacco goods. These groups can be hard to reach with other prevention
measures. An increase in tobacco taxation especially if done across Europe and
with increased police effort to stop smuggling and contraband cigarettes could be
a way to lower the population’s tobacco consumption.
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OBJECTIVES: To estimate trends in medical Computed Tomography (CT) use and
associated radiation exposure in Canada, we assessed the annual effective dose
from CT scans, and estimated the potential related cancer risk. METHODS: CT
examinations in Canada have increased over 400% since 1994 to approximately
4.4M scans annually in 2010. Despite the medical benefits, there is concern regard-
ing radiation-related cancer risk. We developed a mathematical model to estimate
the annual effective dose, and potential cancer risk in Canada from CT, by year,
age, sex, and type of CT exams. RESULTS: From 1994 to 2010, CT examinations
increased from 38 to 127 per 1,000 population (7.8% annual increase). Abdominal /
pelvic CT had the largest annual increase at 10.3%, a five-fold increase in scans,
whereas brain and spine scans grew two-fold. The average effective dose per CT
scan went up from 6.1 mSv to 7.1 mSv. The mean per capita effective dose in-
creased four-fold, at 8.5% annually, from 0.23 mSv to 0.90 mSv. In 2010, males and
females ages 65, had annual doses of 3.2 mSv and 2.5 mSv per capita, respectively.
In the base-case scenario, the potential incidence of radiation induced cancer was
estimated at 2.9 cases per 10,000 population. Extensive sensitivity analyses have
been performed. The risk of cancer in males 65 was 2.9 times greater than for
males 40-64. The risk in females 65was 2.2 times greater than for females 40-64.
The risk in males 65 was 29% higher than in females 65. CONCLUSIONS: For
many patients, the potential benefits of CT scans outweigh foreseeable carcino-
genic risk. Substantial increases in CT technology utilization and recent studies
linking low-dose ionizing radiation to cancer suggest it would be sound policy to
lower patient exposure to ionizing radiation and informing patients about the
potential risk.
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OBJECTIVES: Eribulin mesylate (Eisai, Japan) was approved by the European Com-
mission in March 2011 for the treatment of locally advanced or metastatic breast
cancer in patients who had progressed after at least two chemotherapeutic regi-
mens. The approval, which was granted through the centralised process, was
based on results of the Phase III EMBRACE Trial which demonstrated a statistically
significant increase in overall survival (OS) for the eribulin study arm versus the
treatment of physician’s choice (TPC) arm. This study aims to discern how reim-
bursement bodies in key European countries have assessed the drug, with its high
price, since its approval. METHODS: We reviewed the reimbursement guidance on
eribulin in key European markets and determined whether the decisions were
positive or negative, and how those decisions reflect different weightings of clinical
versus economic (or other) evidence in the assessments. RESULTS: German au-
thorities concluded that eribulin had additional benefits over existing therapies,
despite an initial negative decision by IQWiG, allowing Eisai to enter pricing nego-
tiations. The Italian Medicines Agency and France’s Transparency Commission
both positively recommended the drug for approval in January 2012 and October
2011 respectively. The UK’s NICE as well as the Scottish Medicines Consortium
(SMC) rejected eribulin in April 2012 and October 2011 respectively.CONCLUSIONS:
Despite eribulin’s centralised approval process, reimbursement decisions on the
drug have varied widely among European countries. Although there has been
movement towards greater alignment between European reimbursement agencies
regarding funding decisions, this still has not come to pass as the Eurozone’s fi-
nancial crises threaten to further stymie reimbursement decision harmonisation.
The positive assessments highlight the clinical efficacy of the drug and strength of
the clinical evidence, though questions remain over the economic case.
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OBJECTIVES: To characterize final NICE recommendations for anti-cancer agents
indicated for 15 selected cancers, over time. METHODS: The analysis was based on
a review of 58 drug-indication assessments, representing solid tumor and hema-
tological cancers, published on NICE’s website (January 2001–March 2012). From
each assessment, we extracted the manufacturer’s initial submission base case
incremental cost-effectiveness ratio (ICER), inclusion of a patient access scheme
(PAS), application of end-of-life (EOL) consideration, and final NICE decision.
RESULTS: Average manufacturer base case ICER increased over time, and the per-
centage of drugs not recommended increased from 0% in 2001 to 54% in 2011.
Across all years, NICE recommended 62% (36/58) drug-indication combinations.
Among these, 14% (5/36) included a PAS only, 11% (4/36) satisfied EOL criteria only,
and 22% (8/36) included both a PAS and satisfied EOL criteria. Seventy-two percent
(26/36) had a manufacturer base case ICER  £30,000, of which 27% (7/26) included
a PAS with the initial submission, resulting in a base case ICER  £30,000. Of the 10
recommended drug-indication combinations with a manufacturer base case ICER
 £30,000, 5 included a PAS with the initial manufacturer submission and another
3 satisfied EOL criteria only. Additionally, 11 drug-indication combinations in-
cluded a PAS with initial manufacturer submission, of which 4 satisfied EOL crite-
ria, but none were recommended. CONCLUSIONS: Over time, manufacturer base
case ICERs  £30,000 have become more common, although NICE is more likely to
recommend cancer drugs if the base case ICER is £30,000. Drugs with a base case
ICER  £30,000 are recommended, typically, when the manufacturer and NICE
reach an agreement to reduce cost of treatment through a PAS or when the cancer
drug satisfies EOL criteria. Nevertheless, inclusion of a PAS with the initial manu-
facturer submission does not guarantee a positive recommendation.
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OBJECTIVES: Evaluate how NICE applies the small patient population criterion
(EOL-SPP) of its End-of-Life (EOL) supplemental advice and confirm whether or not
it applies this criterion to currently licensed indications only. METHODS: NICE’s
website was searched for cancer drug single technology assessments (STA) from
January 2009 to May 2012. Only those assessments where EOL considerations ap-
plied were selected for further evaluation. Each STA was evaluated on how NICE
used the EOL-SPP criterion. RESULTS: We identified 25 STAs for which EOL advice
was given for 29 anti-cancer agents, including guidance on one final appraisal
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